Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Roluperidone · MIN-101, CYR-101

Small molecule · developed by Minerva Neurosciences

Phase 3 Most advanced trial
NERV Developer
3 Registered trials

What is Roluperidone?

Roluperidone is an investigational agent studied in negative symptoms of schizophrenia, and in healthy subjects.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
MIN-101, CYR-101
Drug type
Small molecule
Therapy area
Psychiatry
Developer
Minerva Neurosciences (NERV)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 3
UNII
4P31I0M3BF

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07565428 Phase 3 Negative Symptoms of Schizophrenia Recruiting NERV
NCT03397134 Phase 3 Negative Symptoms of Schizophrenia Completed NERV
NCT03038646 Phase 1 Healthy Subjects Completed NERV

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Healthy SubjectsNegative Symptoms of Schizophrenia

More from Minerva Neurosciences

Sources

Updated Oct 25, 2026. Something wrong or missing? Report it on the NERV page.

Follow NERV, the company behind Roluperidone

See NERV's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

NERV catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.